Published January 1, 2022
| Version v1
Journal article
Open
A Highly Potent SARS-CoV-2 Blocking Lectin Protein
Creators
- 1. Bilkent Univ, UNAM Inst Mat Sci & Nanotechnol, TR-06800 Ankara, Turkey
- 2. Ankara Univ, Fac Vet Med, Dept Virol, TR-06110 Ankara, Turkey
- 3. Baskent Univ, Adana Dr Turgut Noyan Med & Res Ctr, Dept Immunol, TR-01250 Adana, Turkey
- 4. Hacettepe Univ, Fac Med, TR-06230 Ankara, Turkey
- 5. Hacettepe Univ, Fac Med, Dept Med Pathol, TR-06230 Ankara, Turkey
- 6. Hacettepe Univ, Fac Med, Dept Med Microbiol, Virol Unit, TR-06230 Ankara, Turkey
Description
The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR(-/-) mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.
Files
bib-d2d91260-2af7-4593-a915-348c971b4f16.txt
Files
(276 Bytes)
| Name | Size | Download all |
|---|---|---|
|
md5:d1ded52d63303c05da4dc1c5ddfb2545
|
276 Bytes | Preview Download |